NCT03603665View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Botulism
Interventions
BIOLOGICAL

NTM-1633

NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.

OTHER

Placebo

0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.

Trial Locations (1)

27710-4000

Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03603665 - A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults | Biotech Hunter | Biotech Hunter